Insulet (NASDAQ:PODD) Hits New 52-Week Low – What’s Next?

Insulet Corporation (NASDAQ:PODD) shares hit a new 52-week low on Tuesday . The stock traded as low as $205.11 and last traded at $208.01, with a volume of 792667 shares trading hands. The stock had previously closed at $208.22.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Oppenheimer decreased their price objective on Insulet from $365.00 to $300.00 and set an “outperform” rating on the stock in a report on Thursday, February 19th. Barclays reiterated an “underweight” rating and issued a $286.00 target price on shares of Insulet in a research note on Thursday, February 19th. The Goldman Sachs Group reduced their target price on Insulet from $363.00 to $326.00 and set a “buy” rating on the stock in a research report on Thursday, February 19th. Sanford C. Bernstein decreased their price target on Insulet from $380.00 to $330.00 and set an “outperform” rating on the stock in a research note on Thursday, February 19th. Finally, Zacks Research cut Insulet from a “strong-buy” rating to a “hold” rating in a report on Monday, January 5th. Twenty analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $354.24.

Insulet Stock Performance

The stock’s fifty day simple moving average is $241.10 and its two-hundred day simple moving average is $285.92. The company has a market cap of $14.58 billion, a price-to-earnings ratio of 59.15, a price-to-earnings-growth ratio of 1.26 and a beta of 1.47. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.48 by $0.07. The business had revenue of $783.80 million during the quarter, compared to the consensus estimate of $768.31 million. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The business’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.15 EPS. Equities research analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Insider Buying and Selling

In other news, Director Michael R. Minogue purchased 2,030 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was bought at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the purchase, the director directly owned 17,483 shares of the company’s stock, valued at $4,304,839.09. The trade was a 13.14% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.39% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Insulet

Several hedge funds and other institutional investors have recently modified their holdings of the company. NewEdge Advisors LLC lifted its position in Insulet by 44.8% during the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after buying an additional 64 shares in the last quarter. Steward Partners Investment Advisory LLC raised its stake in shares of Insulet by 7.3% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 1,127 shares of the medical instruments supplier’s stock valued at $354,000 after acquiring an additional 77 shares during the period. Advisors Asset Management Inc. purchased a new position in shares of Insulet in the 2nd quarter valued at $128,000. J.W. Cole Advisors Inc. acquired a new position in shares of Insulet during the 2nd quarter valued at $262,000. Finally, Schroder Investment Management Group lifted its holdings in shares of Insulet by 30.8% during the 2nd quarter. Schroder Investment Management Group now owns 4,874 shares of the medical instruments supplier’s stock valued at $1,531,000 after acquiring an additional 1,147 shares in the last quarter.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.